21:09 , Jul 16, 2018 |  BC Extra  |  Company News

Management tracks: Cerecor, Sangamo

Neurology play Cerecor Inc. (NASDAQ:CERC) said CFO Mariam Morris is stepping down. She is succeeded by Joe Miller, who was VP of finance at Sucampo Pharmaceuticals Inc., which Mallinckrodt plc (NYSE:MNK) acquired. Additionally, Cerecor hired...
04:51 , Nov 3, 2017 |  BC Week In Review  |  Company News

Novartis offers $3.9B to acquire Advanced Accelerator

Novartis AG (NYSE:NVS; SIX:NOVN) offered to acquire Advanced Accelerator Applications S.A. (NASDAQ:AAAP) for $82 per ADS in a deal the companies say values Advanced Accelerator at $3.9 billion. The price is a 12% premium on...
22:44 , Oct 30, 2017 |  BC Extra  |  Company News

Novartis offers $3.9B to acquire Advanced Accelerator

Novartis AG (NYSE:NVS; SIX:NOVN) offered to acquire Advanced Accelerator Applications S.A. (NASDAQ:AAAP) for $82 per ADS in a deal the companies say values Advanced Accelerator at $3.9 billion. The price is a 12% premium on...
15:20 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

EC approves Lutathera for GEP-NETs

The European Commission approved Lutathera (177-Lu-Dotatate, 177Lu-DOTA0-Tyr3-Octreotate, Lutetium Lu 177 Dotatate) from Advanced Accelerator Applications S.A. (NASDAQ:AAAP) to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Specifically, the approval is for unresectable or metastatic, progressive, well-differentiated, somatostatin receptor-positive...
00:19 , Sep 30, 2017 |  BC Extra  |  Company News

EC approves Lutathera for GEP-NETs

The European Commission approved Lutathera (177-Lu-Dotatate) from Advanced Accelerator Applications S.A. (NASDAQ:AAAP) to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Specifically, the approval is for unresectable or metastatic, progressive, well-differentiated, somatostatin receptor-positive GEP-NETs in adults. A resubmitted...
21:40 , Sep 29, 2017 |  BC Week In Review  |  Company News

Senators call for investigation into Allergan's patent transfer to tribe

Four U.S. senators sent a letter to the Senate Judiciary Committee Sept. 27 calling for an investigation into the patent deal between Allergan plc (NYSE:AGN) and the Saint Regis Mohawk Tribe, saying that the deal...
00:07 , Sep 28, 2017 |  BC Extra  |  Company News

Senators call for investigation into Allergan's patent transfer to tribe

Four U.S. senators sent a letter to the Senate Judiciary Committee Wednesday calling for an investigation into the patent deal between Allergan plc (NYSE:AGN) and the Saint Regis Mohawk Tribe , saying that the deal...
18:48 , Sep 22, 2017 |  BioCentury  |  Politics, Policy & Law

Conferred immunity in IPR

The outcome of Allergan plc ’s gambit to shield its Restasis cyclosporine patents from inter partes review could determine the fate of the IPR system and upset the balance of power between generic and brand...
19:56 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

FDA accepts NDA for Advanced Accelerator's Lutathera

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) said FDA accepted for review a resubmitted NDA for Lutathera (177-Lu-Dotatate, 177Lu-DOTA0-Tyr3-Octreotate, Lutetium Lu 177 Dotatate) to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. The PDUFA date is Jan. 26,...
22:10 , Aug 28, 2017 |  BC Extra  |  Company News

FDA accepts NDA for Lutathera

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) said FDA accepted for review a resubmitted NDA for Lutathera (177-Lu-Dotatate) to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. The PDUFA date is Jan 26, 2018. FDA issued a complete...